Physician profile
Hussein Kiliddar
NPI 1023122306
$4,069.95
in general payments reported to CMS, 2019-2025
29 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $169 · 2021: $167 · 2022: $380 · 2023: $796 · 2024: $893 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.49 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $974.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $504.55 | 2019-2025 | |
| Abbott Laboratories | $398.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $393.54 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $297.76 | 2020-2025 | Dupixent |
| Philips North America LLC | $179.03 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $165.66 | 2025 | Uptravi, Opsumit |
| Jazz Pharmaceuticals INC. | $148.33 | 2021-2025 | |
| Mylan Specialty L.P. | $126.17 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $104.21 | 2019-2024 | |
| Harmony Biosciences LLC | $100.55 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.88 | 2022-2025 | Aralast |
| Axsome Therapeutics, INC. | $73.99 | 2023-2025 | Sunosi |
| Insmed, INC. | $67.80 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $58.75 | 2023-2024 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $53.28 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.61 | 2019-2020 | |
| Inspire Medical Systems, INC. | $46.30 | 2024-2025 | Inspire |
| Vifor Pharma, INC. | $37.00 | 2024-2025 | Zemaira |
| Electromed, INC. | $35.14 | 2024 | Smartvest |
| Mallinckrodt Enterprises LLC | $34.88 | 2019 | |
| Baxter Healthcare | $20.08 | 2023 | Hillrom - Life 2000 Ventilation System |
| Vapotherm INC | $19.35 | 2019 | |
| Optinose US, INC. | $19.29 | 2024 | |
| Grifols USA, LLC | $17.31 | 2020 | |
| Pfizer INC. | $16.81 | 2025 | |
| Genentech USA, INC. | $16.79 | 2019 | |
| Resmed Corp | $12.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Kiliddar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.